Easton Pharmaceuticals Net Income

The latest net income for EAPH is $0 as of September 2023. That compares with $-260K in the prior-year period — up 100.0% year over year. That is below the Healthcare sector average of $17B. Investors often review this figure alongside Easton Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, EAPH's net income moved from $-260K to $0 — a 100.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Easton Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, EAPH currently prints $0 for net income, while the sector average sits near $17B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Easton Pharmaceuticals's growth, margins, and balance sheet.

A net income figure of $0 for EAPH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $17B. Explore the charts below for those layers of context.

After noting EAPH's net income ($0), review year-over-year change from $-260K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.